The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents

Current Drug Delivery

Volumn 7, Issue 1, 2010, Pages 13-20

  Eng, Nelson F ^a   Garlapati, Srinivas ^a   Gerdts, Volker ^a   Potter, Andrew ^a   Babiuk, Lorne A ^b   Mutwiri, George K ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adaptive immunity; Adjuvant; CpG; Delivery; Innate immunity; Microparticles; Polyphosphazene; Vaccine

Indexed keywords

BOVINE SERUM ALBUMIN; CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; MICROSPHERE; PERTUSSIS VACCINE; POLY[DI(CARBOXYLATOPHENOXY)PHOSPHAZENE]; POLY[DI(SODIUMCARBOXYLATOETHYLPHENOXY)PHOSPHAZENE; POLYELECTROLYTE; POLYMER; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; AQUEOUS SOLUTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EXPERIMENTAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS A H3N2; INNATE IMMUNITY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ADAPTATION, PHYSIOLOGICAL; ADJUVANTS, IMMUNOLOGIC; ANTIGENS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; VACCINES;

EID: 77949752913     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110790396481     Document Type: Review

References (57)

1. Singh, M.; O'Hagan, D.T. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol., 2003, 33(5-6), 469-478.
2. Bowersock, T.L., Martin, S. Vaccine delivery to animals. Adv. Drug Deliv. Rev., 1999, 38(2), 167-194.
3. Grubhofer, N.A. Vaccine adjuvants revisited. Open Vet. Sci. J., 2008, 2, 63-67.
4. Singh, M.; O'Hagan, D.T. Recent advances in vaccine adjuvants. Pharm. Res., 2002, 19(6), 715-728.
5. Creagh, E.M.; O'Neill, L.A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol., 2006, 27(8), 352-357.
6. Krieg, A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov., 2006, 5(6), 471-484.
7. Klinman, D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol., 2004, 4(4), 249-258.
8. Wilson, H.L.; Dar, A.; Napper, S.K.; Marianela, L.A.; Babiuk, L.A.; Mutwiri, G.K. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int. Rev. Immunol., 2006, 25(3-4), 183-213.
9. Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.; Hoshino, K.; Horiuchi, T.; Tomizawa, H.; Takeda, K.; Akira, S. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol., 2002, 3(2), 196-200.
10. Jurk, M.; Heil, F.; Vollmer, J.; Schetter, C.; Krieg, A.M.; Wagner, H.; Lipford, G.; Bauer, S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol., 2002, 3(6), 499.
11. Vasilakos, J.P.; Smith, R.M.; Gibson, S.J.; Lindh, J.M.; Pederson, L.K.; Reiter, M.J.; Smith, M.H.; Tomai, M.A. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol., 2000, 204(1), 64-74.
12. Payne, L.G.; Jenkins, S.A.; Woods, A.L.; Grund, E.M.; Geribo, W.E.; Loebelenz, J.R.; Andrianov, A.K.; Roberts, B.E. Poly[di(carboxylatophenoxy) phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine, 1998, 16(1), 92-98.
13. McNeal, M.M.; Rae, M.N.; Ward, R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine, 1999, 17(11-12), 1573-1580.
14. Wu, J.Y.; Wade, W.F.; Taylor, R.K. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect. Immunol., 2001, 69(12), 7695-7702.
15. Payne, L.G.; Van Nest, G.; Barchfeld, G.L.; Siber, G.R.; Gupta, R.K.; Jenkins, S.A. In: The Utility of PCPP as a Parenteral Adjuvant for Diverse Antigens. Haaheim, L.; Ed.; Modulation of the Immune Response to Vaccine Antigens; International Association of Biological Standardization: Geneva, 1997.
16. Lu, Y.; Salvato, M.S.; Pauza, C.D.; Li, J.; Sodroski, J.; Manson, K.; Wyand, M.; Letvin, N.; Jenkins, S.; Touzjian, N.; Chutkowski, C.; Kushner, N.; LeFaile, M.; Payne, L.G.; Roberts, B. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1996, 12(2), 99-106.
17. Andrianov, A.K.; Payne, L.G. Polymeric carriers for oral uptake of microparticulates. Adv. Drug Deliv. Rev., 1998, 34(2-3), 155-170.
18. Mutwiri, G.; Benjamin, P.; Soita, H.; Townsend, H.; Yost, R.; Roberts, B.; Andrianov, A.K.; Babiuk, L.A. Poly[di(sodium carboxylatoethylphenoxy) phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine, 2007, 25(7), 1204-1213.
19. Andrianov, A.K.; Payne, L.G. In: Polyphosphazene Hydrogen Microspheres for Protein Delivery. Cohen, S.; Bernstein, H.; Eds.; Microparticulate Systems for the Delivery of Proteins and Vaccines; Marcel Dekker: New York, 1996, 127-147.
20. Andrianov, A.K.; Marin, A.; Chen, J. Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy) phosphazene]. Biomacromolecules, 2006, 7(1), 394-399.
21. Mutwiri, G.; Benjamin, P.; Soita, H.; Babiuk, L.A. Coadministration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine, 2008, 26(22), 2680-2688.
22. Constant, S.L.; Bottomly, K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol., 1997, 15, 297-322.
23. Holmgren, J.; Harandi, A.M.; Czerkinsky, C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert. Rev. Vaccines., 2003, 2(2), 205-217.
24. Eng, N.F; Garlapati, S.; Lai, K.; Gerdts, V.; Mutwiri, G.K. Polyphosphazenes enhance mucosal and systemic immune responses in mice immunized intranasally with influenza antigens. Open Vaccine. J. 2009, 2, 134-143.
25. Mutwiri, G.; van Drunen Littel-van den Hurk, S.; Babiuk, L.A. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv. Drug Deliv. Rev., 2009, 61(3), 226-232.
26. Mutwiri, G.K.; Babiuk, L.A. In: The potential of polyphosphazenes in modulating vaccine-induced immune responses II: Investigations in large animals. Andrianov, A.; Ed.; Polyphosphazenes for Biomedical Applications; John Wiley & Sons: Toronto, 2009, 77-84.
27. Andrianov, A.K.; Marin, A.; Roberts, B.E. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules, 2005, 6(3), 1375-1379.
28. Andrianov, A.K.; Sargent, J.R.; Sule, S.S.; LeGolvan, M.P.; Woods, A.L.; Jenkins, S.A.; Payne, L.G. Synthesis, physicochemical properties and immunoadjuvant activity of water-soluble phosphazene polyacids. J. Bioact. Compat. Polymers, 1998, 13(4), 243-256.
29. Bouveret Le Cam, N.N.; Ronco, L.; Francon, A.; Blondeau, C.; Fanget, B. Adjuvants for influenza vaccine. Res. Immunol., 1998, 149, 19-23.
30. Gilbert, P.B.; Chiu,Y.L.; Allen, M.; Lawrence, D.N.; Chapdu, C.; Israel, H.; Holman, D.; Keefer, M.C.; Wolff, M.; Frey, S.E. Longterm safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine, 2003, 21(21-22), 2933-2947.
31. Davis, H.L.; Weeratna, R.; Waldschmidt, T.J.; Tygrett, L.; Schorr, J.; Krieg, A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol., 1998, 160(2), 870-876.
32. Ioannou, X.P.; Griebel, P.; Hecker, R.; Babiuk, L.A.; van Drunen Littel-van den Hurk, S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J. Virol., 2002, 76(18), 9002-9010.
33. Ioannou, X.P.; Gomis, S.M.; Karvonen, B.; Hecker, R.; Babiuk, L.A.; van Drunen Littel-van den Hurk, S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine, 2002, 21(1-2), 127-137.
34. Wack, A.; Baudner, B.C.; Hilbert, A.K.; Manini, I.; Nuti, S.; Tavarini, S.; Scheffczik, H.; Ugozzoli, M.; Singh, M.; Kazzaz, J.; Montomoli, E.; Del, G.G.; Rappuoli, R.; O'Hagan, D.T. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine, 2008, 26(4), 552-561.
35. Mutwiri, G.K.; Nichani, A.K.; Babiuk, S.; Babiuk, L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control Release, 2004, 97(1), 1-17.
36. Gomis, S.; Babiuk, L.; Godson, D.L.; Allan, B.; Thrush, T.; Townsend, H.; Willson, P.; Waters, E.; Hecker, R.; Potter, A. Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect. Immun., 2003, 71(2), 857-863.
37. Gomis, S.; Babiuk, L.; Allan, B.; Willson, P.; Waters, E.; Ambrose, N.; Hecker, R.; Potter, A. Protection of neonatal chicks against a lethal challenge of Escherichia coli using DNA containing cytosinephosphodiester-guanine motifs. Avian Dis., 2004, 48(4), 813-822.
38. Taghavi, A.; Allan, B.; Mutwiri, G.; Foldvari, M.; Van Kessel, A.; Willson, P.; Babiuk, L.; Potter, A.; Gomis, S. Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr. Drug Deliv., 2009, 6(1), 76-82.
39. Mapletoft, J.W.; Oumouna, M.; Kovacs-Nolan, J.; Latimer, L.; Mutwiri, G.; Babiuk, L.A.; van Drunen Littel-van den Hurk, S. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J. Gen. Virol., 2008, 89(Pt 1), 250-260.
40. Connors, M.; Giese, N.A.; Kulkarni, A.B.; Firestone, C.Y.; Morse, H.C., III; Murphy, B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol., 1994, 68(8), 5321-5325.
41. Waris, M.E.; Tsou, C.; Erdman, D.D.; Day, D.B.; Anderson, L.J. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J. Virol., 1997, 71(9), 6935-6939.
42. Peyre, M.; Audran, R.; Estevez, F.; Corradin, G.; Gander, B.; Sesardic, D.; Johansen, P. Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J. Control Release, 2004, 99(3), 345-355.
43. Mutwiri, G.; Bowersock, T.L.; Babiuk, L.A. Microparticles for oral delivery of vaccines. Expert. Opin. Drug Deliv., 2005, 2(5), 791-806.
44. van der Lubben, I.; Kersten, G.; Fretz, M.M.; Beuvery, C.; Coos, V.J.; Junginger, H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine, 2003, 21(13-14), 1400-1408.
45. Jones, D.H.; McBride, B.W.; Thornton, C.; O'Hagan, D.T.; Robinson, A.; Farrar, G.H. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect. Immun., 1996, 64(2), 489-494.
46. Cahill, E.S.; O'Hagan, D.T.; Illum, L.; Barnard, A.; Mills, K.H.; Redhead, K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine, 1995, 13(5), 455-462.
47. Moldoveanu, Z.; Novak, M.; Huang, W.Q.; Gilley, R.M.; Staas, J.K.; Schafer, D.; Compans, R.W.; Mestecky, J. Oral immunization with influenza virus in biodegradable microspheres. J. Infect. Dis., 1993, 167(1), 84-90.
48. de Jong, S.; Chikh, G.; Sekirov, L.; Raney, S.; Semple, S.; Klimuk, S.; Yuan, N.; Hope, M.; Cullis, P.; Tam, Y. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother., 2007, 56(8), 1251-1264.
49. Conway, M.A.; Madrigal-Estebas, L.; McClean, S.; Brayden, D.J.; Mills, K.H. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine, 2001, 19(15-16), 1940-1950.
50. Singh, M.; Singh, O.; Talwar, G.P. Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys. Pharm. Res., 1995, 12(11), 1796-1800.
51. Payne, L.G.; Jenkins, S.A.; Andrianov, A.; Roberts, B.E. Watersoluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm. Biotechnol., 1995, 6, 473-493.
52. Andrianov, A.K.; Chen, J. Polyphosphazene microspheres: Preparation by ionic complexation of phosphazene polyacids with spermine. J. Appl. Polym. Sci., 2006, 101, 414-419.
53. Eldridge, J.H.; Staas, J.K.; Meulbroek, J.A.; Tice, T.R.; Gilley, R.M. Biodegradable and biocompatible poly(DL-lactide-coglycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun., 1991, 59(9), 2978-2986.
54. O'Hagan, D.T.; Jeffery, H.; Davis, S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine, 1993, 11(9), 965-969.
55. Albrecht, P.; Ennis, F.A.; Saltzman, E.J.; Krugman, S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr., 1977, 91(5), 715-718.
56. Karron, R.A.; Steinhoff, M.C.; Subbarao, E.K.; Wilson, M.H.; Macleod, K.; Clements, M.L.; Fries, L.F.; Murphy, B.R. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr. Infect. Dis. J., 1995, 14(1), 10-16.
57. Burstyn, D.G.; Baraff, L.J.; Peppler, M.S.; Leake, R.D.; St. Geme, J., Jr.; Manclark, C.R. Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect. Immun., 1983, 41(3), 1150-1156.